Determination of spatial and temporal distribution of microglia by 230nm-high-resolution, high-throughput automated analysis reveals different amyloid plaque populations in an APP/PS1 mouse model of alzheimer's disease

Current Alzheimer Research

Volumn 8, Issue 7, 2011, Pages 781-788

  Scheffler, Katja ^a   Stenzel, Jan ^a   Krohn, Markus ^a   Lange, Cathleen ^a   Hofrichter, Jacqueline ^a   Schumacher, Toni ^a   Brüning, Thomas ^a   Plath, Anne Sophie ^a,b   Walker, Lary ^c   Pahnke, Jens ^a,b  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AD; Alzheimer's disease; Beta amyloid; Blood brain barrier; Dementia; Immune therapy; Inflammation; Microglia; Neurodegeneration

Indexed keywords

AMYLOID BETA PROTEIN;

AGING; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CELL ACTIVATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOLOGY; DISEASE MODEL; FEMALE; INFLAMMATION; MALE; MICROGLIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENILE PLAQUE; SPATIAL ORIENTATION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, TRANSGENIC; MICROGLIA; PLAQUE, AMYLOID; PRESENILIN-1;

EID: 80054088628     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720511797633179     Document Type: Article

References (39)

1. Czech C, Tremp G, Pradier L. Presenilins and Alzheimer's disease: biological functions and pathogenic mechanisms. Prog Neurobiol 60(4): 363-384 (2000).
2. Frautschy SA, Yang F, Irrizarry M, Hyman B, Saido TC, Hsiao K, et al. Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol 152(1): 307-317 (1998).
3. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 451(7179): 720-724 (2008).
4. Sastre M, Klockgether T, Heneka MT. Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. Int J Dev Neurosci 24(2-3): 167-176 (2006).
5. Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 10(11): 1387-1394 (2007).
6. Streit WJ. Microglial senescence: does the brain's immune system have an expiration date? Trends Neurosci 29(9): 506-510 (2006).
7. Schwartz M, Butovsky O, Brück W, Hanisch UK. Microglial phenotype: is the commitment reversible? Trends Neurosci 29(2): 68-74 (2006).
8. Cotman CW, Tenner AJ, Cummings BJ. beta-Amyloid converts an acute phase injury response to chronic injury responses. Neurobiol Aging 17(5): 723-731 (1996).
9. Napoli I, Neumann H. Microglial clearance function in health and disease. Neuroscience 158(3): 1030-1038 (2009).
10. Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, et al. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 273(49): 32730-32738 (1998).
11. Takaki Y, Iwata N, Tsubuki S, Taniguchi S, Toyoshima S, Lu B, et al. Biochemical identification of the neutral endopeptidase family member responsible for the catabolism of amyloid beta peptide in the brain. J Biochem (Tokyo) 128(6): 897-902 (2000).
12. Grathwohl SA, Kälin RE, Bolmont T, Prokop S, Winkelmann G, Kaeser SA, et al. Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia. Nat Neurosci 12(11): 1361-1363 (2009).
13. Simard AR, Rivest S. Neuroprotective properties of the innate immune system and bone marrow stem cells in Alzheimer's disease. Mol Psychiatry 11(4): 327-335 (2006).
14. Bolmont T, Haiss F, Eicke D, Radde R, Mathis CA, Klunk WE, et al. Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci 28(16): 4283-4292 (2008).
15. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-diseaselike pathology in the PDAPP mouse. Nature 400(6740): 173-177 (1999).
16. Brody DL, Holtzman D.M. Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 31: 175-193 (2008).
17. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98(15): 8850-8855 (2001).
18. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 5(5): 452-457 (2002).
19. Bales KR, Tzavara ET, Wu S, Wade MR, Bymaster FP, Paul SM, et al. Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody. J Clin Invest 116(3): 825-832 (2006).
20. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61(1): 46-54 (2003).
21. Kunisch E, Fuhrmann R, Roth A, Winter R, Lungershausen W, Kinne RW. Macrophage specificity of three anti-CD68 monoclonal antibodies (KP1, EBM11, and PGM1) widely used for immunohistochemistry and flow cytometry. Ann Rheum Dis 63(7): 774-784 (2004).
22. Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, et al. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain 131(Pt 12): 3299-3310 (2008).
23. Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, et al. Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol 65(11): 1040-1048 (2006).
24. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372(9634): 216-223 (2008).
25. Morgan D. The role of microglia in antibody-mediated clearance of amyloid-beta from the brain. CNS Neurol Disord Drug Targets 8(1): 7-15 (2009).
26. Wilcock DM, Munireddy SK, Rosenthal A, Ugen KE, Gordon MN, Morgan D. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis 15(1): 11-20 (2004).
27. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 1(1): 24 (2004).
28. Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, et al. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 7(9): 940-946 (2006).
29. Pahnke J, Wolkenhauer O, Krohn M, Walker LC. Clinicopathologic function of cerebral ABC transporters - implications for the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 5(4): 396-405 (2008).
30. Pahnke J, Mix E, Knoblich R, Müller J, Zschiesche M, Schubert B, et al. Overexpression of glial cell line-derived neurotrophic factor induces genes regulating migration and differentiation of neuronal progenitor cells. Exp Cell Res 297(2): 484-494 (2004).
31. Vogelgesang S, Warzok RW, Cascorbi I, Kunert-Keil C, Schroeder E, Kroemer HK, et al. The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. Curr Alzheimer Res 1(2): 121-125 (2004).
32. Pahnke J, Walker LC, Scheffler K, Krohn M. Alzheimer's disease and blood-brain barrier function-Why have anti-beta-amyloid therapies failed to prevent dementia progression? Neurosci Biobehav Rev 33(7): 1099-1108 (2009).
33. Napoli I, Neumann H. Microglial clearance function in health and disease. Neuroscience 158(3): 1030-1038 (2009).
34. El Khoury JB, Moore KJ, Means TK, Leung J, Terada K, Toft M, et al. CD36 mediates the innate host response to beta-amyloid. J Exp Med 197(12): 1657-1666 (2003).
35. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308(5726): 1314-1318 (2005).
36. Giulian D, Vaca K, Corpuz M. Brain glia release factors with opposing actions upon neuronal survival. J Neurosci 13(1): 29-37 (1993).
37. Pihlaja R, Koistinaho J, Malm T, Sikkilä H, Vainio S, Koistinaho M. Transplanted astrocytes internalize deposited beta-amyloid peptides in a transgenic mouse model of Alzheimer's disease. Glia 56(2): 154-163 (2008).
38. Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci 28(33): 8354-8360 (2008).
39. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9(4): 448-452 (2003).